LCM
BRTX icon

Lynwood Capital Management’s BioRestorative Therapies BRTX Stock Holding History

Lynwood Capital Management’s Portfolio BRTX Stock Details BRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-20,000
Closed -$35.8K – 61
2023
Q3 		$35.8K Buy
+20,000
New +$50.4K 0.09% 39

Other funds holding BRTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WA
Wealth Alliance Mellville, New York $1.01B AUM 19.71% 1-Year Est. Return
Mariner
Mariner Overland Park, Kansas $85.7B AUM 24.21% 1-Year Est. Return
SG
StoneX Group New York $1.86B AUM 21.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Lynwood Capital Management's BRTX Position: Q4 2023 in Review

Lynwood Capital Management sold out of BioRestorative Therapies (BRTX) in Q4 2023, closing a stake of 20,000 shares — an estimated $35.8K sold.

Lynwood Capital Management first reported a position in BRTX in Q3 2023 and held it in 1 quarter. The position peaked at $35.8K in Q3 2023. 13 funds tracked by Wall St. Rank hold BRTX as of Q4 2023.

  • Lynwood Capital Management reported no remaining BioRestorative Therapies position as of Q4 2023 after selling out during the quarter.
  • Lynwood Capital Management sold 20,000 BioRestorative Therapies shares in Q4 2023, an estimated $35.8K.
  • Lynwood Capital Management first reported a position in BioRestorative Therapies in Q3 2023 and held it in 1 quarter.
  • Lynwood Capital Management's BioRestorative Therapies position peaked at $35.8K in Q3 2023.
  • 13 funds tracked by Wall St. Rank held BioRestorative Therapies as of Q4 2023.

Based on Lynwood Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.